Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Transferrin receptor 2

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    36 result(s) found for: Transferrin receptor 2. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2011-004561-33 Sponsor Protocol Number: ThromboAct Start Date*: 2014-05-23
    Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin III, Abteilung für Gastroenterologie und Hepatologie
    Full Title: A randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT® versus placebo on platelet activity in patients with iron defi...
    Medical condition: iron deficiency in chronic inflammatory bowel disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003406-40 Sponsor Protocol Number: RK2017 Start Date*: 2017-09-08
    Sponsor Name:Université catholique de Louvain
    Full Title: Repetitive blood donations and endurance sport performance: does iron supplementation limit the negative effects on hematological parameters?
    Medical condition: healthy subjects moderately active undergoing repeated blood donations
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002218-39 Sponsor Protocol Number: AFX01-04 Start Date*: 2005-08-16
    Sponsor Name:Affymax, Inc.
    Full Title: A Phase 2, Open-label, Multi-center, Sequential Dose Finding Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Multiple Doses of AF37702 Injection (HematideTM) in Chronic Kidney Diseas...
    Medical condition: Anaemia in patients with chronic kidney disease not on dialysis (pre-dialysis patients).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003855-38 Sponsor Protocol Number: PIERAID-2013 Start Date*: 2014-09-26
    Sponsor Name:Miguel Giovanni Uriol Rivera
    Full Title: Benefits of paricalcitol (Selective vitamin D receptor activator indicated for the prevention and treatment of secondary hyperparathyroidism) on anaemia of inflammation in dialysis patients receiv...
    Medical condition: Anaemia of inflammation in patients with chronic kidney disease on haemodialysis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010282-23 Sponsor Protocol Number: Bruxism-01 Start Date*: 2010-10-26
    Sponsor Name:Tandvården SU/Mölndal
    Full Title: A randomized, open-label, cross-over study to explore a potential involvement of a dopamine related dysfunction as a mechanism behind bruxism
    Medical condition: Patients with severe oral bruxism according to Polysomnographic cut-off criteria for bruxism: more than 4 bruxism episodes per hour, more than 6 bruxism bursts per episode and/or 25 bruxism bursts ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028037 Movement disorders (incl parkinsonism) HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004194-40 Sponsor Protocol Number: MYOCARDIAL-IRON Start Date*: 2017-02-07
    Sponsor Name:Instituto de Investigación Sanitaria INCLIVA
    Full Title: Changes in Myocardial Iron Content Following Administration of Intravenous Iron
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-001525-27 Sponsor Protocol Number: SNOXH94C201 Start Date*: 2012-07-19
    Sponsor Name:NOXXON Pharma AG
    Full Title: Phase IIa study to characterize the effects of the Spiegelmer® NOX-H94 on anemia of chronic disease in patients with cancer
    Medical condition: anemia of chronic disease in patients with cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004864 10007050 Cancer LLT
    16.0 100000004851 10054310 Anemia of chronic disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003542-17 Sponsor Protocol Number: FISM_IRON-MDS Start Date*: 2019-05-06
    Sponsor Name:FONDAZIONE ITALIANA SINDROMI MIELODISPLASTICHE ETS
    Full Title: Early and low dose Deferasirox (3.5 mg/kg FCT) to suppress NTBI and LPI as early intervention to prevent tissue iron overload in lower risk MDS
    Medical condition: Adult patients with low risk MDS
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028532 Myelodysplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-000130-33 Sponsor Protocol Number: ORION-HF Start Date*: 2022-12-23
    Sponsor Name:Hannover Medical School
    Full Title: A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)
    Medical condition: Patients with heart failure, iron deficiency and anaemia with either reduced or preserved left ventricular ejection fraction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 100000004849 10024106 Left heart failure LLT
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    20.0 100000004849 10078289 Heart failure with reduced ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000849-32 Sponsor Protocol Number: 1/2022 Start Date*: 2022-05-10
    Sponsor Name:Helsinki University Hospital
    Full Title: The effect of tenofovir disoproxil fumarate (TDF) versus tenofovir alafenamide (TAF) on proximal small intestine – a potential mechanism to explain opposing effects on body weight
    Medical condition: HIV-positive people who have good and stable treatment response for HIV-medication which includes either tenofovir disoproxil (TDF) or tenoforvir alafenamide (TAF)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005592-13 Sponsor Protocol Number: FERRICHFII Start Date*: 2014-02-27
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Mechanisms of Exercise Benefit with Intravenous Iron in Chronic Heart Failure: The Ferric Iron in Heart Failure (FERRIC HF) II Trial
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024585-22 Sponsor Protocol Number: WILK3 Start Date*: 2011-03-25
    Sponsor Name:Imperial College Academic Healthsciences Centre
    Full Title: What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002499-15 Sponsor Protocol Number: A536-04 Start Date*: 2012-12-19
    Sponsor Name:ACCELERON PHARMA INC
    Full Title: A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia
    Medical condition: β-thalassemia intermedia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10062923 Thalassemia intermedia LLT
    15.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000348-22 Sponsor Protocol Number: KER047-IR-201 Start Date*: 2021-08-10
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA
    Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001206-35 Sponsor Protocol Number: ACEI-COVID-19 Start Date*: 2020-04-14
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Stopping ACE-inhibitors in COVID-19 - a randomized, controlled clinical trial
    Medical condition: The study will investigate infections with the new SARS-CoV2 virus. Current studies show that the SARS-CoV2 virus penetrates human cells via the angiotensin converting enzyme II (ACE2) receptor 2. ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003604-31 Sponsor Protocol Number: PREFER-HF Start Date*: 2017-02-09
    Sponsor Name:José Luis Morales Rull, Institut de Recerca Biomédica Lleida IRB Hospital Arnau de Vilanova Servicio de Medicina Interna
    Full Title: Effects of intravenous iron therapy with ferric carboxymaltose compared with oral iron therapy in heart failure with preserved ejection fraction and iron deficiency. ( PREFER-HF)
    Medical condition: Patients with heart failure with preserved ejection fraction ( HFpEF) and iron deficency anemia.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-005053-37 Sponsor Protocol Number: IVOFER-HF Start Date*: 2019-02-08
    Sponsor Name:José Luis Morales Rull. Institut de Recerca Biomèdica de Lleida (IRBLleida)
    Full Title: Effect on the functional capacity of treatment with intravenous iron carboxymaltose or oral iron sucrosomial in patients with heart failure with depressed left ventricular ejection fraction and iro...
    Medical condition: Patients with heart failure with reduced ejection fraction ( HFrEF) and iron deficency.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000331-63 Sponsor Protocol Number: HGB-210 Start Date*: 2021-02-09
    Sponsor Name: bluebird bio, Inc.
    Full Title: A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003121-94 Sponsor Protocol Number: P-Monofer-IBD-02 Start Date*: 2011-12-14
    Sponsor Name:Pharmacosmos A/S
    Full Title: A Prospective, Non-controlled, Safety Study of Intravenous Iron Isomaltoside 1000 (Monofer®) administered by a High Dosing Regimen in Subjects with Inflammatory Bowel Disease (PROMISE)
    Medical condition: Inflammatory Bowel Disease (IBD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004851 10002062 Anaemia iron deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-004608-37 Sponsor Protocol Number: FER-CARS-02 Start Date*: 2007-07-27
    Sponsor Name:Vifor Pharma, Vifor (International) Ltd.
    Full Title: A randomised double-blind controlled phase III study to compare the efficacy and safety of intravenous ferric carboxymaltose (Ferinject®) with placebo in patients with chronic heart failure and iro...
    Medical condition: iron deficiency in patients with chronic heart failure
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022970 Iron deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) CZ (Completed) GR (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 22:19:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA